Topline data were announced from two phase 3 trials evaluating ulixacaltamide in patients with essential tremor.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback